United States : VISTERRA secures up-to-$204.5M BARDA Contract.
Visterra said that the BARDA contract includes funding for performing preclinical toxicology studies, conducting clinical trials, manufacturing of materials for clinical trials and continued optimization of manufacturing processes, and associated regulatory activities intended to advance VIS410.
Visterra separately in addition said that it plans to advance VIS410 into further clinical trials in patients with influenza A, after the compound showed a statistically significant viral response over placebo in a Phase IIa influenza viral challenge study, and achieved its primary endpoint of reduction in viral shedding.
Subjects treated with VIS410 experienced a 92% reduction in viral shedding and resolved upper respiratory symptoms two days earlier than subjects in the placebo group. The primary endpoint was gained after a pre-specified interim analysis, and as a result, Visterra said, it has stopped the comparative portion of the study.
VIS140 is a broad spectrum human monoclonal antibody designed and engineered to neutralize all strains of influenza A, including mutated strains and strains that have lately emerged. VIS410 is a direct acting anti-viral that inhibits hemagglutinin-mediated cell membrane fusion, thereby preventing viral replication.
Visterra through its Hierotope Platform to identify novel targets and engineer drugs against these targets has identified a conformational epitope on the stem region of the influenza hemagglutinin protein. As per to the company, this epitope, or hierotope, is not only conserved across all influenza subtypes, but is also resistant to virus mutation.
Visterra said that it is developing VIS410 as a single administration treatment for hospitalized patients with influenza A infection, including seasonal and potential pandemic strains.
The BARDA contract comprises a 40-month base period with committed funding of $29.1 million, as well as option periods that, if exercised in full by BARDA, would expand the contract to a total of five years and increase the total funding up to $204.5 million. The full funding would support Visterra s plans to submit a Biologics License Application for VIS410 to the FDA.
Brian J.G. Pereira, M.D., the company s president and CEO said in a statement, Visterra is proud to play an important role in addressing the significant public health concern of seasonal influenza A and the growing threat of emerging strains of influenza A .
Visterra was established based on scientific work developed in the laboratory of Ram Sasisekharan, Ph.D., and licensed from MIT.
The BARDA contract comes a year to the month that Visterra secured $30 million in Series B financing to advance the development of VIS410 and a second product candidate, VIS513, a human monoclonal antibody for dengue that has been shown to broadly neutralize all four dengue virus serotypes.
The financing was co-led by new investors Merck Research Labs Venture Fund, Vertex Venture Holdings Ltd., and Temasek, with participation by another new investor, Cycad Group, and previous investors Polaris Partners, Flagship Ventures, Omega Funds and Alexandria Venture Investments. The previous investors joined The Bill & Melinda Gates Foundation in a $26 million series A financing in 2012.
[c] 2015 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 8, 2015|
|Previous Article:||United States : Parsons Wins Shindagha Corridor Project in Dubai.|
|Next Article:||United States : Governor Cuomo Announces $13.9 Million Repaving Project for Long Island.|